PUBLISHER: The Business Research Company | PRODUCT CODE: 1945357
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945357
Implantable neurostimulation devices are medical devices designed to deliver electrical stimulation to specific areas of the nervous system to treat various neurological and psychological conditions. These devices are surgically implanted into the body to modulate nerve activity, offering a sophisticated approach for managing conditions that may not respond adequately to medication alone, thereby enhancing patients' quality of life.
The primary types of implantable neurostimulation devices include spinal cord stimulation (SCS), gastric electric stimulation (GES), deep brain stimulation (DBS), sacral nerve stimulation (SNS), vagus nerve stimulation (VNS), and others. Spinal cord stimulation (SCS) therapy uses mild electrical currents to block pain signals from reaching the brain, providing effective management for chronic pain conditions. These devices are applied in treating pain management, Parkinson's disease, urinary and fecal incontinence, epilepsy, gastroparesis, and other conditions. They are used by various end-users, including hospitals, clinics, and ambulatory surgical centers.
Tariffs are impacting the implantable neurostimulation devices market by increasing costs of imported microelectronics, electrodes, batteries, sensors, and software-enabled control units. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported advanced components, while Asia-Pacific faces higher manufacturing and export costs. These tariffs are increasing therapy system prices and slowing adoption in cost-sensitive healthcare systems. However, they are also driving local manufacturing, regional R&D investment, and development of cost-efficient neurostimulation platforms.
The implantable neurostimulation devices market research report is one of a series of new reports from The Business Research Company that provides implantable neurostimulation devices market statistics, including implantable neurostimulation devices industry global market size, regional shares, competitors with a implantable neurostimulation devices market share, detailed implantable neurostimulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable neurostimulation devices industry. This implantable neurostimulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The implantable neurostimulation devices market size has grown rapidly in recent years. It will grow from $5.62 billion in 2025 to $6.27 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to rising prevalence of neurological disorders, expansion of pain management treatments, adoption of implantable stimulation technologies, increasing clinical acceptance of neuromodulation, availability of implantable electronic systems.
The implantable neurostimulation devices market size is expected to see rapid growth in the next few years. It will grow to $10.02 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing demand for non-pharmacological therapies, rising focus on precision neuromodulation, expansion of outpatient neurological treatments, growing investment in brain-machine interface research, increasing innovation in stimulation algorithms. Major trends in the forecast period include increasing deployment of advanced neurostimulation therapies, rising adoption of rechargeable stimulation devices, growing use of personalized neuromodulation treatments, expansion of multi-indication neurostimulation systems, enhanced focus on long-term therapy effectiveness.
The increasing prevalence of neurological disorders is expected to drive the growth of the implantable neurostimulation devices market in the coming years. Neurological disorders are conditions that affect the structure or function of the nervous system, resulting in symptoms such as paralysis, seizures, and cognitive impairments. Greater exposure to risk factors such as high blood pressure, developmental abnormalities, trauma, or injury contributes to higher detection rates of these disorders. Implantable neurostimulation devices are used to modulate nerve activity and alleviate symptoms when conventional treatments are ineffective or insufficient. For example, according to the Alzheimer's Association, a US-based non-profit organization, an estimated 6.9 million Americans aged 65 and older were living with Alzheimer's disease in 2024, with 73% being 75 years or older. This number is projected to reach 12.7 million by 2050. Thus, the rising prevalence of neurological disorders is expected to fuel the demand for implantable neurostimulation devices.
Companies in the implantable neurostimulation devices market are focusing on developing advanced systems, such as rechargeable brain-sensing neurostimulators, to provide more personalized and adaptive therapy for patients with movement and neurological disorders. These devices are implanted to record real-time brain signals while delivering targeted stimulation, allowing clinicians to fine-tune therapy based on individual neural activity and long-term treatment requirements. For instance, in January 2024, Medtronic, a US-based medical device company, received U.S. Food and Drug Administration (FDA) approval for its Percept RC neurostimulator, a rechargeable deep brain stimulation (DBS) system featuring exclusive BrainSense technology. The device captures and tracks brain signals to optimize personalized therapy. It offers a service life of at least 15 years, flexible directional stimulation programming, and rapid recharging capabilities, providing patients with a durable and customizable option for managing movement disorders.
In September 2023, Amber Therapeutics, a UK-based provider of neuromodulation therapies, acquired Bioinduction for an undisclosed amount. This acquisition strengthens Amber's strategic capabilities by incorporating Bioinduction's implantable-device hardware, engineering expertise, and manufacturing know-how to support next-generation neuromodulation solutions. It also accelerates the development and commercialization of Amber-UI by integrating proven implantable neurostimulation technology into Amber's platform. Bioinduction is a UK-based manufacturer of implantable neurostimulation devices.
Major companies operating in the implantable neurostimulation devices market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, St. Jude Medical LLC, LivaNova PLC, Nevro Corp., Axonics Inc., NeuroPace Inc., Bioness Inc., Saluda Medical Pty Ltd., SceneRay Co. Ltd., NeuroMetrix Inc., Synapse Biomedical Inc., NeuroSigma Inc., Nuvectra Corporation, MicroTransponder Inc., Curonix LLC, Inspire Medical Systems Inc., SetPoint Medical Corporation, ElectroCore Inc.
North America was the largest region in the implantable neurostimulation devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable neurostimulation devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the implantable neurostimulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The implantable neurostimulation devices market consists of sales of responsive neurostimulation systems, peripheral nerve stimulation systems, cerebral spinal fluid shunt systems and electroceutical devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Implantable Neurostimulation Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses implantable neurostimulation devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for implantable neurostimulation devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The implantable neurostimulation devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.